Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

Mes dernières consult.
Most popular
Analysis summary4-Traders Strategies

A valuable trading opportunity

share with twitter share with LinkedIn share with facebook
share via e-mail
12/29/2014 | 03:33pm

Gilead Sciences stock is back on an attractive purshase level, investors should take advantage from this opportunity.

The American biotechnology company displays outstanding fundamentals, with an attractive valuation and a strong profitability (Net margin of 48.8% in 2014). The business has considerable growth potential as underlined by Thomson Reuters estimates: EPS should quadruple this year, from 1.81 dollars in 2013 to 7.28. Furthermore, analysts mostly keep a 'buyer' bias, targetting on average a 30% appreciation potential.

Technically, the security evolves in a bullish trend on the long term. Prices fell recently, and are back now on the USD 89.45 support. A techical rebound seems under construnction near to this threshold, which is likely to bring back the bullish trend on the short term. Moving averages positively oriented on weekly data should support this upsurge.

Therefore, an excellent opportunity arises to buy Gilead Sciences shares on a cheap price in order to benefit from its appreciation potential. The target price will be set at USD 100.3 then USD 114.2 by extension. A stop loss should be placed under the current USD 89.4 support.

Anas Boumedian
© Zonebourse.com 2014
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2017 25 816 M
EBIT 2017 15 661 M
Net income 2017 10 511 M
Debt 2017 12 742 M
Yield 2017 2,76%
P/E ratio 2017 9,84
P/E ratio 2018 12,83
EV / Sales 2017 4,37x
EV / Sales 2018 4,95x
Capitalization 100 B
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Duration : Period : Week
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders